HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Helen Usansky Selected Research

Ado-Trastuzumab Emtansine

1/2021ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Helen Usansky Research Topics

Disease

2Bronchiectasis
10/2022 - 01/2022
1Cystic Fibrosis (Mucoviscidosis)
10/2022
1Periodontal Diseases (Periodontal Disease)
10/2022
1Infections
10/2022
1Neoplasms (Cancer)
01/2021
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
12/2012

Drug/Important Bio-Agent (IBA)

2Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
10/2022 - 01/2022
2brensocatibIBA
10/2022 - 01/2022
1Leukocyte Elastase (Neutrophil Elastase)IBA
10/2022
1Cathepsin GIBA
10/2022
1Myeloblastin (Proteinase 3)IBA
10/2022
1Serine Proteases (Serine Protease)IBA
01/2022
1PF-06263507IBA
01/2021
1AntigensIBA
01/2021
1Ado-Trastuzumab EmtansineIBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2021
1Glycoproteins (Glycoprotein)IBA
01/2021
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2012